395 related articles for article (PubMed ID: 29984503)
41. Cardiovascular Protection in the Treatment of Type 2 Diabetes: A Review of Clinical Trial Results Across Drug Classes.
Paneni F; Lüscher TF
Am J Cardiol; 2017 Jul; 120(1S):S17-S27. PubMed ID: 28606340
[TBL] [Abstract][Full Text] [Related]
42. Complementing insulin therapy to achieve glycemic control.
Barnett AH
Adv Ther; 2013 Jun; 30(6):557-76. PubMed ID: 23797471
[TBL] [Abstract][Full Text] [Related]
43. Impact of EMPA-REG OUTCOME
Naing S; Poliyedath A; Khandelwal S; Sigala T
Postgrad Med; 2016 Nov; 128(8):822-827. PubMed ID: 27701934
[TBL] [Abstract][Full Text] [Related]
44. Cardiovascular benefits of SGLT2 inhibitors and GLP-1 receptor agonists in Type 2 diabetes.
Med Lett Drugs Ther; 2019 Feb; 61(1566):26-28. PubMed ID: 30845101
[No Abstract] [Full Text] [Related]
45. Effects of Incretin-Based Therapies and SGLT2 Inhibitors on Skeletal Health.
Egger A; Kraenzlin ME; Meier C
Curr Osteoporos Rep; 2016 Dec; 14(6):345-350. PubMed ID: 27709509
[TBL] [Abstract][Full Text] [Related]
46. Evaluating second-line treatment options for type 2 diabetes: focus on secondary effects of GLP-1 agonists and DPP-4 inhibitors.
Boland CL; Degeeter M; Nuzum DS; Tzefos M
Ann Pharmacother; 2013 Apr; 47(4):490-505. PubMed ID: 23548652
[TBL] [Abstract][Full Text] [Related]
47. Results from Cardiovascular Outcome Trials in Diabetes.
Muñoz Torres M; Muñoz Garach A
Endocrinol Nutr; 2016; 63(7):317-9. PubMed ID: 27324936
[No Abstract] [Full Text] [Related]
48. [The combination of GLP-1 analogs and SGLT2 inhibitors : new perspectives ?].
Ritz C; Jaafar J; Philippe J
Rev Med Suisse; 2017 May; 13(565):1134-1139. PubMed ID: 28639755
[TBL] [Abstract][Full Text] [Related]
49. An update on DPP-4 inhibitors in the management of type 2 diabetes.
Cahn A; Cernea S; Raz I
Expert Opin Emerg Drugs; 2016 Dec; 21(4):409-419. PubMed ID: 27809608
[TBL] [Abstract][Full Text] [Related]
50. Cardiovascular Effects of Incretin-Based Therapies.
White WB; Baker WL
Annu Rev Med; 2016; 67():245-60. PubMed ID: 26768240
[TBL] [Abstract][Full Text] [Related]
51. The Changing Landscape of Pharmacotherapy for Diabetes Mellitus: A Review of Cardiovascular Outcomes.
Wu L; Gunton JE
Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31766545
[TBL] [Abstract][Full Text] [Related]
52. Type 2 Diabetes Medication and Cardiovascular Benefits.
Shrestha A; Munankarmi R
S D Med; 2021 Mar; 74(3):132-135. PubMed ID: 34232594
[TBL] [Abstract][Full Text] [Related]
53. Incretin-based agents in type 2 diabetic patients at cardiovascular risk: compare the effect of GLP-1 agonists and DPP-4 inhibitors on cardiovascular and pancreatic outcomes.
Zhang Z; Chen X; Lu P; Zhang J; Xu Y; He W; Li M; Zhang S; Jia J; Shao S; Xie J; Yang Y; Yu X
Cardiovasc Diabetol; 2017 Mar; 16(1):31. PubMed ID: 28249585
[TBL] [Abstract][Full Text] [Related]
54. New Glucose-Lowering Agents for Diabetic Kidney Disease.
de Vos LC; Hettige TS; Cooper ME
Adv Chronic Kidney Dis; 2018 Mar; 25(2):149-157. PubMed ID: 29580579
[TBL] [Abstract][Full Text] [Related]
55. Clinical implications of cardiovascular outcome trials in type 2 diabetes.
Mellbin LG; Wang A; Rydén L
Herz; 2019 May; 44(3):192-202. PubMed ID: 30805659
[TBL] [Abstract][Full Text] [Related]
56. [Novel antidiabetic drugs and cardiovascular complications].
Pareek M; Mortensen MB; Løfgren B; Nielsen ML; Olsen MH; Andersen NH
Ugeskr Laeger; 2018 Feb; 180(6):. PubMed ID: 29429477
[TBL] [Abstract][Full Text] [Related]
57. Comparing SGLT-2 inhibitors to DPP-4 inhibitors as an add-on therapy to metformin in patients with type 2 diabetes: A systematic review and meta-analysis.
Mishriky BM; Tanenberg RJ; Sewell KA; Cummings DM
Diabetes Metab; 2018 Mar; 44(2):112-120. PubMed ID: 29477373
[TBL] [Abstract][Full Text] [Related]
58. Sodium-glucose cotransporter 2 inhibitors combined with dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes: a review of current clinical evidence and rationale.
Yassin SA; Aroda VR
Drug Des Devel Ther; 2017; 11():923-937. PubMed ID: 28356718
[TBL] [Abstract][Full Text] [Related]
59. [Management of Type 2 Diabetes: a Practical Approach].
Donath M
Praxis (Bern 1994); 2016 Jun; 105(12):699-702. PubMed ID: 27269776
[TBL] [Abstract][Full Text] [Related]
60. SGLT-2 Inhibitors and Cardiovascular Risk in Diabetes Mellitus: A Comprehensive and Critical Review of the Literature.
Imprialos K; Faselis C; Boutari C; Stavropoulos K; Athyros V; Karagiannis A; Doumas M
Curr Pharm Des; 2017; 23(10):1510-1521. PubMed ID: 28120716
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]